Connect Biopharma Holdings Limited (CNTB) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Connect Biopharma Holdings Limited (CNTB) trades at $2.28 with AI Score 14/100 (Grade F). Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company focused on developing immune modulators for serious autoimmune and inflammatory diseases. Market cap: $144M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for CNTB: CNTB does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CNTB against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CNTB: 2/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Connect Biopharma Holdings Limited (CNTB) Healthcare & Pipeline Overview
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company headquartered in China, specializing in immune modulators for autoimmune and inflammatory diseases. Its pipeline includes lead candidate CBP-201 in Phase IIb for allergic conditions, alongside other compounds targeting various inflammatory pathways, positioning it within the high-risk, high-reward biotechnology sector.
What Is the Investment Thesis for CNTB?
Connect Biopharma Holdings Limited presents a research profile centered on its clinical-stage pipeline targeting significant autoimmune and inflammatory disease markets. The company's primary value driver is the progression of CBP-201, an anti-interleukin-4 receptor alpha antibody, currently in Phase IIb clinical trials for atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Successful advancement through these trials and subsequent Phase III studies would significantly de-risk the asset and validate its therapeutic potential in large patient populations. Additionally, CBP-307, a sphingosine 1-phosphate receptor 1 modulator in Phase II for autoimmune-related inflammation, provides pipeline diversification and addresses another substantial therapeutic area. The company's preclinical assets, CBP-174 and CBP-233, offer future growth avenues. With a market capitalization of $144M, the company's valuation reflects its early-stage development profile. Key considerations include the high capital requirements for clinical trials, the inherent risks of drug development outcomes, and the competitive landscape within the biotechnology sector.
Based on FMP financials and quantitative analysis
CNTB Key Highlights
Market Capitalization: $0.13 billion, reflecting its clinical-stage valuation and early market presence.
- Gross Margin: 100.0%, indicative of a company without commercialized product sales and associated cost of goods.
- Return on Equity (ROE): -102.9%, typical for a clinical-stage biopharmaceutical company investing heavily in research and development.
- Debt-to-Equity Ratio: 1.63, suggesting a reliance on debt financing relative to equity to fund its operations.
- Beta: -0.20, indicating an inverse correlation with the broader market, which is an unusual characteristic for a biotechnology stock.
Who Are CNTB's Competitors?
CNTB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.21% | $196M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ICCC ImmuCell Corporation | $10.13 | +3.79% | $91.6M | 77 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
| MDXG MiMedx Group, Inc. | $4.45 | +2.53% | $649M | 90 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CNTB's Key Strengths?
Focused pipeline with lead candidates (CBP-201, CBP-307) in mid-stage clinical development (Phase IIb and Phase II).
- Expertise in immune modulation, targeting diverse pathways relevant to autoimmune and inflammatory diseases.
- Diverse therapeutic targets including IL-4Rα, S1P1, H3, and IL-33, addressing multiple disease areas.
- Headquartered in China, potentially offering access to a large patient population for clinical trials and future market.
What Are CNTB's Weaknesses?
Clinical-stage company with no commercialized products and thus no current revenue from sales.
- Negative Return on Equity (-102.9%) and reliance on external funding for extensive R&D activities.
- High R&D costs inherent to drug development, leading to significant cash burn.
- Small employee base (62 employees) compared to larger pharmaceutical competitors, potentially limiting resource allocation.
What Could Drive CNTB Stock Higher?
CNTB catalyst: Release of Phase IIb clinical trial data for CBP-201 in atopic dermatitis, which could significantly influence market perception and future development plans.
- Initiation of Phase III clinical trials for CBP-201 in any of its target indications (atopic dermatitis, asthma, or chronic rhinosinusitis with nasal polyps), signaling progression towards commercialization.
- Advancement of CBP-307 into Phase III clinical trials for autoimmune-related inflammation diseases, further validating its potential and expanding the pipeline's late-stage assets.
- Progression of preclinical candidates CBP-174 (for chronic itch) or CBP-233 (for T helper 2 inflammation) into Phase I clinical trials, demonstrating a robust and advancing early-stage pipeline.
What Are the Key Risks for CNTB?
Financial-distress signal — its Altman Z-Score of -13.48 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- High risk of clinical trial failure for lead candidates CBP-201 and CBP-307, which could lead to significant delays, increased costs, or complete discontinuation of development programs.
- Dependence on external financing to fund extensive research and development activities, potentially leading to future equity offerings and dilution for existing shareholders.
- Intense competition from larger pharmaceutical companies and other biotechnology firms developing similar immune modulators for autoimmune and inflammatory diseases.
- Regulatory hurdles and delays in obtaining marketing approval from health authorities in various jurisdictions, impacting the timeline and cost of commercialization.
- Intellectual property challenges and the ability to maintain robust patent protection for its proprietary compounds against potential infringement or challenges from competitors.
What Are the Growth Opportunities for CNTB?
- Growth opportunity 1: Advancement of CBP-201 through late-stage clinical trials for inflammatory allergic diseases. CBP-201, an anti-interleukin-4 receptor alpha antibody, is currently in Phase IIb for atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. These indications represent multi-billion dollar markets globally, with significant unmet needs for effective, targeted therapies. Successful progression into Phase III and subsequent regulatory approval would de-risk the asset considerably, paving the way for potential commercialization and substantial revenue generation within the next 3-7 years, depending on trial timelines and regulatory processes.
- Growth opportunity 2: Successful development and commercialization of CBP-307 for autoimmune-related inflammation. CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, is in Phase II clinical trials. S1P1 modulators have demonstrated efficacy in various autoimmune conditions by regulating T cell mobilization. Advancing CBP-307 through later clinical stages could position Connect Biopharma to address a broad spectrum of autoimmune diseases, potentially expanding its market reach into areas with high patient populations and demand for new treatment options over the next 5-10 years.
- Growth opportunity 3: Progression of preclinical assets, CBP-174 and CBP-233, into clinical development. The company's pipeline includes CBP-174 for chronic itch and CBP-233 for T helper 2 inflammation. Moving these novel compounds from preclinical studies into Phase I and beyond would validate Connect Biopharma's research capabilities and provide future growth drivers. Each successful transition into clinical trials adds potential long-term value and diversification to the company's therapeutic portfolio, offering new market opportunities beyond its lead candidates in the 7-12 year timeframe.
- Growth opportunity 4: Formation of strategic partnerships or licensing agreements with larger pharmaceutical companies. As a clinical-stage biopharmaceutical company, Connect Biopharma could leverage its promising pipeline assets to secure collaborations for late-stage development, manufacturing, and global commercialization. Such partnerships could provide non-dilutive funding, access to extensive resources, and established commercial infrastructures, accelerating market entry and reducing financial risk. These collaborations could materialize at various stages of clinical development, potentially within the next 2-5 years, depending on clinical data readouts.
- Growth opportunity 5: Expansion of therapeutic indications for existing pipeline candidates. Beyond the primary indications, successful clinical data for CBP-201 or CBP-307 could support investigations into additional inflammatory or autoimmune conditions where their mechanisms of action are relevant. Broadening the approved indications for a single drug candidate can significantly increase its total addressable market and revenue potential without requiring the development of entirely new compounds. This strategy could unfold over the next 5-10 years as clinical data matures and regulatory pathways are explored.
What Are CNTB's Competitive Advantages?
- Proprietary drug candidates with distinct mechanisms of action, such as the anti-IL-4Rα antibody (CBP-201) and the S1P1 modulator (CBP-307).
- Intellectual property protection through patents covering its novel compounds, formulations, and therapeutic applications, providing market exclusivity upon approval.
- Accumulated clinical trial data and scientific expertise in specific therapeutic areas, building a knowledge base difficult for competitors to replicate quickly.
- Specialized R&D capabilities and a focused pipeline in immune modulation, allowing for deep expertise in a complex biological field.
What Does CNTB Do?
Connect Biopharma Holdings Limited, founded in 2012 and headquartered in Taicang, China, operates as a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immune modulators. The company's core mission is to address significant unmet medical needs in serious autoimmune diseases and inflammation. Its product pipeline is centered around several key candidates, each targeting specific immunological pathways. The lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is currently undergoing Phase IIb clinical trials. This candidate is being investigated for its potential to treat a range of inflammatory allergic diseases, including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps, representing a substantial market opportunity. Beyond CBP-201, Connect Biopharma's portfolio includes CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1 (S1P1). S1P1 is a crucial regulator of T cell mobilization, and CBP-307 is in Phase II clinical development for the treatment of various autoimmune-related inflammatory diseases. The company also maintains a preclinical pipeline with promising early-stage assets. These include CBP-174, a small molecule histamine receptor 3 antagonist designed for oral administration, which is being developed to treat chronic itch associated with skin inflammation. Another preclinical asset is CBP-233, a humanized antibody specifically targeting interleukin-33 (IL-33), a cytokine known to be involved in T helper 2 inflammation. Connect Biopharma's strategic focus is on advancing these immune modulators through rigorous clinical development to potentially bring new therapeutic options to patients worldwide.
What Products and Services Does CNTB Offer?
- Discover and develop immune modulators for serious autoimmune diseases and inflammation.
- Advance CBP-201, an anti-interleukin-4 receptor alpha antibody, through Phase IIb clinical trials.
- Investigate CBP-201 for inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps.
- Develop CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, in Phase II for autoimmune-related inflammation diseases.
- Conduct preclinical research on CBP-174, a small molecule histamine receptor 3 antagonist, for chronic itch associated with skin inflammation.
- Explore CBP-233, a humanized antibody against interleukin-33, for its role in T helper 2 inflammation.
- Operate as a clinical-stage biopharmaceutical company, focusing on R&D rather than commercial sales.
How Does CNTB Make Money?
- Primarily focused on the research and development of novel drug candidates for immune-mediated diseases.
- Aims to generate future revenue through the successful clinical development, regulatory approval, and commercialization of its proprietary therapies.
- Potential for out-licensing agreements or strategic partnerships with larger pharmaceutical companies to fund late-stage development and facilitate global market access.
- Currently relies on capital raises, investments, and potentially grants to finance extensive research and clinical trial operations.
- Future revenue streams would derive from product sales or royalty payments following market authorization of its drug candidates.
What Industry Does CNTB Operate In?
Connect Biopharma Holdings Limited operates within the highly specialized and competitive biotechnology industry, specifically focusing on immune modulators for autoimmune and inflammatory diseases. This segment of the healthcare sector is characterized by significant unmet medical needs and a growing global market driven by increasing disease prevalence and demand for more effective and targeted therapies. The company's strategy to develop novel compounds like anti-IL-4Rα antibodies and S1P1 modulators positions it against both established pharmaceutical giants and other innovative biotech firms. The industry is capital-intensive, with long development cycles and high regulatory hurdles, but offers substantial rewards for successful drug commercialization. Connect Biopharma's clinical-stage status means it is currently focused on research and development, aiming to capture a share of this expanding market through its differentiated pipeline.
Who Are CNTB's Key Customers?
- Future patients suffering from inflammatory allergic diseases like atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps.
- Individuals with autoimmune-related inflammatory diseases who could benefit from CBP-307.
- Healthcare providers, including dermatologists, pulmonologists, allergists, and rheumatologists, who would prescribe approved therapies.
- Potential pharmaceutical partners interested in co-development, licensing, or commercialization agreements for its pipeline assets.
Connect Biopharma Holdings Limited (CNTB) Valuation Context
Valued at $144M, CNTB is classified as a micro-cap stock. Relative to its peer group, CNTB's quantitative score of 14/100 is below the peer average of 76/100.
CNTB Revenue & Earnings Trend
In Q2 2026, CNTB generated $2.9M in top-line revenue, marking a sequential increase of 6018.8%. The company recorded a net loss of $17.3M, with diluted EPS of $-0.27. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare.
Company Profile
Connect Biopharma Holdings Limited operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Barry D. Quart. CNTB has traded publicly since 2021.
Key Financial Metrics
Return on assets is -54.2%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.23 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Connect Biopharma Holdings Limited's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -13.48 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Connect Biopharma Holdings Limited has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 49.9% above estimates on average.
Forward Outlook
Wall Street analysts project Connect Biopharma Holdings Limited revenue of about $5.1M for fiscal 2026, with EPS near $-1.10. The estimate reflects 6 contributing analysts.
CNTB Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Connect Biopharma's pipeline, mirroring moves seen before positive trial data in similar biotech firms.
- Community sentiment reflects optimism about Connect's atopic dermatitis drug candidate, potentially a game-changer in a competitive market.
- The overall market perception is leaning towards positive, with analysts highlighting the unmet need in the atopic dermatitis space, similar to the early enthusiasm for novel treatments in other disease areas.
- Bullish community views focus on the potential for a major partnership or acquisition, a common trajectory for biopharma companies with promising late-stage assets.
Bear Case
- Recent community sentiment shows concerns about competition from larger pharmaceutical companies with established market presence. Think of how smaller players struggled against giants in the early days of the PCSK9 inhibitor market.
- Market perception acknowledges the inherent risks in clinical trials, with potential for unexpected setbacks, like those experienced by other biotech firms with promising but ultimately unsuccessful drug candidates.
- Insider activity, while showing some buying, also reveals significant selling, raising questions about long-term prospects, similar to concerns raised during periods of heavy insider selling at companies facing regulatory hurdles.
- Bearish community views express apprehension about the company's cash burn rate and potential need for further dilutive financing, a worry that has plagued many biotechs with lengthy development timelines.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $3M | -$17M | -$0.27 |
| Q2 2025 | $48,000 | -$13M | -$0.23 |
| Q4 2024 | $698,000 | -$9M | -$0.42 |
Based on FMP financials and quantitative analysis
CNTB Latest News
No recent news available for CNTB.
CNTB Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CNTB.
Price Targets
Wall Street price target analysis for CNTB.
CNTB MoonshotScore
What does this score mean?
The MoonshotScore rates CNTB 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Barry D. Quart
Chief Executive Officer
Dr. Barry D. Quart serves as the Chief Executive Officer of Connect Biopharma Holdings Limited, overseeing the company's strategic direction and operational execution. With extensive experience in the biopharmaceutical sector, Dr. Quart has a proven track record in drug development and corporate leadership. His career has focused on advancing novel therapies through clinical stages, particularly in areas of high unmet medical need, demonstrating a deep understanding of the scientific and regulatory landscape.
Track Record: Under Dr. Quart's leadership, Connect Biopharma has advanced its lead product candidate, CBP-201, into Phase IIb clinical trials for multiple inflammatory allergic diseases. He has been instrumental in guiding the development of the company's pipeline, including CBP-307 into Phase II, and overseeing preclinical programs for CBP-174 and CBP-233, focusing on building a robust portfolio of immune modulators.
Connect Biopharma Holdings Limited ADR Information Sponsored
Connect Biopharma Holdings Limited trades as an American Depositary Receipt (ADR), which is a certificate issued by a U.S. bank representing shares in a foreign stock. For CNTB, these ADRs allow U.S. investors to buy shares of a company based in Taicang, China, on a U.S. exchange, simplifying cross-border investment without directly trading on the home market.
- Home Market Ticker: Unknown primary stock exchange in China
- ADR Level: 2
- ADR Ratio: 1:1
What Investors Ask About Connect Biopharma Holdings Limited (CNTB) — Healthcare
What does the AI Score mean for CNTB?
CNTB holds an AI Score of 14/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company focused on developing immune modulators for serious autoimmune and inflammatory diseases. Its pipeline includes lead …
What does Connect Biopharma Holdings Limited do?
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company focused on the discovery and development of immune modulators. The company aims to treat serious autoimmune diseases and inflammation by targeting specific immunological pathways.
What is Connect Biopharma Holdings Limited's drug pipeline status?
Connect Biopharma Holdings Limited maintains a focused pipeline of immune modulators. Its lead product candidate, CBP-201, an anti-interleukin-4 receptor alpha antibody, is currently in Phase IIb clinical trials for multiple inflammatory allergic diseases, including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps.
What are the main risks for CNTB?
The primary risks for Connect Biopharma Holdings Limited stem from its nature as a clinical-stage biopharmaceutical company. A significant risk is the potential for clinical trial failures, which could lead to substantial financial losses and hinder the advancement of its drug candidates.
What are the key factors to evaluate for CNTB?
Connect Biopharma Holdings Limited (CNTB) holds an AI score of 14/100 (low). Connect Biopharma Holdings Limited presents a research profile centered on its clinical-stage pipeline targeting significant autoimmune and inflammatory disease markets. Not financial advice.
How frequently does CNTB data refresh on this page?
CNTB's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CNTB's recent stock price performance?
Connect Biopharma Holdings Limited (CNTB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focused pipeline with lead candidates (CBP-201, CBP-307) in mid-stage clinical development (Phase IIb and Phase II). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CNTB overvalued or undervalued right now?
Connect Biopharma Holdings Limited (CNTB) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research CNTB before investing?
Before investing in Connect Biopharma Holdings Limited (CNTB), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- No FMP PEER TICKERS were provided, so the 'competitors' array is empty.
- CEO tenureYears could not be determined from provided data.
- Specific primary stock exchange in China for home market could not be determined from provided data.